Autoimmune thyroid disease elicited by NY-ESO-1 vaccination

Thyroid

Volumn 24, Issue 2, 2014, Pages 390-394

  Vita, Roberto ^a   Guarneri, Fabrizio ^b   Agah, Ravin ^c   Benvenga, Salvatore ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c PALO ALTO MEDICAL FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIGENS, NEOPLASM; CANCER VACCINES; COMBINED MODALITY THERAPY; EPITOPES; FEMALE; GRAVES DISEASE; HUMANS; MEMBRANE PROTEINS; SARCOMA, SYNOVIAL; SEQUENCE HOMOLOGY, AMINO ACID; VACCINATION;

EID: 84894112901     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0170     Document Type: Article

References (27)

1. Hamnvik OP, Larsen PR, Marqusee E 2011 Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst 103:1572-1587.
2. Turk MJ, Wolchok JD, Guevara-Patino JA, Goldberg SM, Houghton AN 2002 Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol Rev 188:122-135.
3. Reuschenbach M, Von Knebel Doeberitz M, Wentzensen N 2009 A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 58:1535-1544.
4. Chen YT, Old LJ 1999 Cancer-testis antigens: targets for cancer immunotherapy. Cancer J Sci Am 5:16-17.
5. O'Meara MM, Disis ML 2011 Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept. OMICS 15:579-588.
6. Diefenbach CSM, Gnjatic S, Sabbatini P, Aghajanian C, Hensley ML, Spriggs DR, Iasonos A, Lee H, Dupont B, Pezzulli S, Jungbluth AA, Old LJ, Dupont J 2008 Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res 14:2740-2748.
7. Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ 1997 Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25:3389-3402. (Software freely available at http://blast.ncbi.nlm.nih.gov/Blast.cgi. Accessed January 15, 2013).
8. Sathiamurthy M, Hickman HD, Cavett JW, Zahoor A, Prilliman K, Metcalf S, Fernandez Vina M, Hildebrand WH 2003 Population of the HLA ligand database. Tissue Antigens 61:12-19.
9. Van Doorn L, Eskens FA, Visser TJ, Van Der Lugt A, Mathijssen RH, Peeters RP 2011 Sorafenib induced thyroiditis in two patients with epatocelular carcinoma. Thyroid 21:197-202.
10. Sato S, Muraishi K, Tani J, Sasaki Y, Tokubuchi I, Tajiri Y, Yamada K, Suekane S, Miyajima J, Matsuoka K, Hiromatsu Y 2010 Clinical characteristics of thyroid abnormalities induced by sutinib treatment in Japanese patients with renal cell carcinoma. Endocr J 57:873-880.
11. Jonasch E, Haluska FG 2001 Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6:34-55.
12. CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK. 2008 Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359:1786-1801.
13. Di Giacomo AM, Biagioli M, Maio M 2010 The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 37:499-507.
14. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M 1999 Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 340:1075-1079.
15. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA 2011 Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917-924.
16. Robson NC, McAlpine T, Knights AJ, Schnurr M, Shin A, Chen W, Maraskovsky E, Cebon J 2010 Processing and crosspresentation of individual HLA-A, -B, or-C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery. Blood 116:218-225.
17. *0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients. Vaccine 28:5338-5346.
18. Jäger E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jäger D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A 1998 Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265-270.
19. Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF 2001 CD4 (+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci USA 98:3964-3969.
20. Guarneri F, Benvenga S 2007 Environmental factors and genetic background that interact to cause autoimmune thyroid disease. Curr Opin Endocrinol Diabetes Obes 14:398-409.
21. Mackin JF, Canary JJ, Pittman CS 1974 Thyroid storm and its management. N Engl J Med 291:1396-1398.
22. Dong RP, Kimura A, Okubo R, Shinagawa H, Tamai H, Nishimura Y, Sasazuki T 1992 HLA-A and DPB1 loci confer susceptibility to Graves' disease. Hum Immunol 35:165-172.
23. Ratanachaiyavong S, McGregor AM 1994 HLA-DPB1 polymorphisms on the MHC-extended haplotypes of families of patients with Graves' disease: two distinct HLA-DR17 haplotypes. Eur J Clin Invest 24:309-315.
24. Ofosu MH, Dunston G, Henry L, Ware D, Cheatham W, Brembridge A, Brown C, Alarif L 1996 HLA-DQ3 is associated with Graves' disease in African-Americans. Immunol Invest 25:103-110.
25. Orhan Y, Azezli A, Carin M, Aral F, Sencer E, Molvalilar S 1993 Human lymphocyte antigens (HLA) and Graves' disease in Turkey. J Clin Immunol 13:339-343.
26. Jacobson EM, Huber A, Tomer Y 2008 The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology. J Autoimmun 30:58-62.
27. Yeo PP, Chan SH, Thai AC, Ng WY, Lui KF, Wee GB, Tan SH, Lee BW, Wong HB, Cheah JS 1989 HLA Bw46 and DR9 associations in Graves' disease of Chinese patients are ageand sex-related. Tissue Antigens 34:179-184.